Uncategorized

Zion Pharma Limited, a Chinese biotechnology company focused on the development of brain-penetrable compounds, announced that Roche has acquired the global rights to Zion’s lead program, ZN-A-1041.

Ochre Bio, an innovator in chronic liver disease medicine development, has announced its participation in upcoming investor and industry conferences, sharing expert perspectives and insights across liver disease and RNA therapeutics, building and scaling startups, and the future of medicine.

Genentech, a member of the Roche Group, announced that the U.S. Food and Drug Administration has accepted the company’s supplemental Biologics License Application for Vabysmo® for the treatment of macular edema following retinal vein occlusion.

Interius BioTherapeutics, a preclinical stage gene therapy company developing novel methods for in vivo cell-specific gene delivery, announced a manufacturing partnership with WuXi Advanced Therapies, a global Contract Testing, Development and Manufacturing Organization.

Verona Pharma plc, a clinical-stage biopharmaceutical company focused on respiratory diseases, announces its financial results for the first quarter ended March 31, 2023, and provides a corporate update.

Una enfermedad inflamatoria crónica que se asocia con una morbilidad significativa más allá de las manifestaciones cutáneas.

Takeda plans to cut about 186 staff members across Massachusetts, beginning in early July. 

The activist investor’s plan shows a lack of understanding of the company and  genomics industry, the maker of DNA sequencers said.

The company said it plans to use the proceeds of the sale to pay down its debt.

The first-quarter report comes weeks after the operator announced its plans to acquire Geisinger Health and form a new nonprofit with the purpose of acquiring and operating other nonprofit systems.